Most recent guideline publication:
Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022)
Tables provided in the main manuscript of the guideline:
|Table 1. Assignment of predicted G6PD phenotype based on genotype|
|Table 2. Drug-specific risk level and associated strength of recommendation for patients with G6PD deficiency|
|Table 3. Recommended therapeutic use of high risk drugs in relation to G6PD phenotype|
|Table 4. Recommended therapeutic use of medium risk drugs in relation to G6PD phenotype|
|Table 5. Recommended therapeutic use of low-to-no risk drugs in relation to G6PD phenotype|
|Table 6. Recommended therapeutic use of primaquine in relation to G6PD phenotype|
Supplement to: Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022)
Tables included in the supplementa:
aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.
- September 2018 update to 2014 guideline: The CPIC authors recommend that the G6PD A variant be categorized as IV/normal function (previously II-IV/Deficient-Normal function) based on new evidence supporting function (PMID 27040960 and 30206300). This change has been incorporated into G6PD allele definition table.